Compare M & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | M | RYTM |
|---|---|---|
| Founded | 1830 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 5.8B |
| IPO Year | 2002 | 2017 |
| Metric | M | RYTM |
|---|---|---|
| Price | $25.28 | $89.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 14 |
| Target Price | $20.09 | ★ $131.14 |
| AVG Volume (30 Days) | ★ 7.2M | 555.5K |
| Earning Date | 05-27-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.97% | N/A |
| EPS Growth | 12.08 | ★ 28.34 |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $22,621,000,000.00 | N/A |
| Revenue This Year | N/A | $55.34 |
| Revenue Next Year | N/A | $86.06 |
| P/E Ratio | $108.63 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.99 | $60.99 |
| 52 Week High | $25.65 | $122.20 |
| Indicator | M | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 71.92 | 54.54 |
| Support Level | $16.74 | $82.43 |
| Resistance Level | N/A | $92.51 |
| Average True Range (ATR) | 1.09 | 4.22 |
| MACD | 0.32 | 0.24 |
| Stochastic Oscillator | 93.12 | 48.58 |
Founded in 1858 and based in New York City, Macy's operates about 430 eponymous stores, 60 stores under the Bloomingdale's (full-price and outlet) and Bloomie's names, and more than 170 freestanding Bluemercury specialty beauty stores. Macy's also operates e-commerce sites and licenses Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances constituted 64% of 2025 net retail sales.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.